ReviewAnnals of medicine2025
Cell-specific roles of autophagy in liver fibrosis: implications for targeted pharmacotherapy.
Review in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Liver fibrosis: Pathogenesis and innovative nanoparticle-based therapeutic strategies.International journal of pharmaceutics: X · 2026Review
- Metabolic reprogramming in hepatic stellate cells: unveiling a novel therapeutic target for liver fibrosis.Frontiers in physiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver fibrosis represents a pivotal stage in the progression from chronic liver disease to cirrhosis, characterized by intricate pathological alterations in both parenchymal and non-parenchymal cells. Autophagy, a fundamental mechanism for maintaining intracellular homeostasis, plays a critical role in these processes. This study aims to elucidate the cell type-specific roles of autophagy in liver fibrosis and propose targeted intervention strategies.
methodsWe systematically reviewed the functional roles of autophagy in hepatocytes, macrophages, hepatic stellate cells (HSCs), and liver sinusoidal endothelial cells (LSECs) by analyzing current experimental and mechanistic evidence. We further conceptualized therapeutic approaches based on selective modulation of autophagic activity in different cell populations.
resultsIn hepatocytes, autophagy exerts protective effects by reducing lipid accumulation and preventing apoptosis caused by lipid metabolism disorders. In macrophages, autophagy regulates polarization and suppresses inflammatory cytokine release, thereby attenuating inflammation and slowing fibrosis progression. Conversely, autophagy in HSCs and LSECs exhibits dual effects: it may accelerate fibrosis by promoting cell activation and extracellular matrix remodeling or mitigate fibrosis by inhibiting these processes. These findings underscore the cell context-dependent role of autophagy during fibrogenesis.
conclusionsSelective enhancement or inhibition of autophagy in distinct liver cell types offers a promising strategy for regulating fibrosis. This approach provides new insights and a theoretical basis for developing targeted therapies for liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.